返回 Agenda
Session2: Clinical Trial Model in Post COVID-19
Session Chair(s)
Toshiko Ishibashi, PhD, RN
Oncology Medical Science Department, Medical Affairs Division
Daiichi Sankyo Co., Ltd., Japan
Eri Sekine
Executive Vice President Data Business
CMIC Co., Ltd, Japan
Speaker(s)
Recasting the Model in a Post-COVID World
Mark Scullion
Novartis Corporation, United States
Global Head Trial Monitoring,
Proposal from TransCelerate; Modernizing Clinical Trial Conduct
Kazumi Yabe
Bristol-Myers Squibb, Japan
Clinical Operations
The Impact of COVID-19 on Clinical Trial Activities from the CRO Perspective
Dai Nagaki
CMIC Co., Ltd., Japan
Clincial Leader, Clinical Research Dept.
Clinical Trial Model in Post COVID-19 - Site Perspectives
Yasutoshi Kuboki, MD, PhD
National Cancer Center Hospital East, Japan
Experimental Therapeutics
Experience of Clinical Trials during the COVID-19 Pandemic_CRC’s Perspective in Korea
Elisabet Kim, MSN, RN
Asan Medical Center, Korea, Republic of
Clinical Research Coordinator